ArticleBMC medical imaging2025
Multimodal diagnostic tools and advanced data models for detection of prodromal Parkinson's disease: a scoping review.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Artificial Intelligence and Digital Biomarkers for Early Detection and Monitoring of Neurological Disorders: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- From fragmented neurotechnologies to closed-loop brain health systems: integrating artificial intelligence, digital health, digital twins, and advanced materials for brain disorders.Frontiers in bioengineering and biotechnology · 2026Article
- Construction and effectiveness test of multimodal data fusion prediction model for intracranial infection after severe craniocerebral injury in children based on deep learning.BMC neurology · 2025Article
- The Effect of Data Leakage and Feature Selection on Machine Learning Performance for Early Parkinson's Disease Detection.Bioengineering (Basel, Switzerland) · 2025Article
- Redefining Non-Motor Symptoms in Parkinson's Disease.Journal of personalized medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta. PD is diagnosed by a combination of motor symptoms including bradykinesia, resting tremors, rigidity and postural instability. Prodromal PD is the stage preceding the onset of classic motor symptoms of PD. The diagnosis of prodromal PD remains challenging despite many available diagnostic modalities.
aimThis scoping review aims to investigate and explore the current diagnostic modalities used to detect prodromal PD, focusing particularly on multimodal imaging analysis and AI-based approaches.
methodsWe adhered to the PRISMA-SR guidelines for scoping reviews. We conducted a comprehensive literature search at multiple databases such as PubMed, Scopus, Web of Science, and the Cochrane Library from inception to July 2024, using keywords related to prodromal PD and diagnostic modalities. We included studies based on predefined inclusion and exclusion criteria and performed data extraction using a standardized form.
resultsThe search included 9 studies involving 567 patients with prodromal PD and 35,643 control. Studies utilized various diagnostic approaches including neuroimaging techniques and AI-driven models. sensitivity ranging from 43 to 84% and specificity up to 96%. Neuroimaging and AI technologies showed promising results in identifying early pathological changes and predicting PD onset. The highest specificity was achieved by neuromelanin-sensitive imaging model, while highest sensitivity was achieved by standard 10-s electrocardiogram (ECG) + Machine learning model.
conclusionAdvanced diagnostic modalities such as AI-driven models and multimodal neuroimaging revealed promising results in early detection of prodromal PD. However, their clinical application as screening tool for prodromal PD is limited because of the lack of validation. Future research should be directed towards using Multimodal imaging in diagnosing and screening for prodromal PD. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.